Board of Directors2021-01-16T10:05:40+00:00

Board of Directors

Dr. John Fox
Dr. John FoxChairman of the board
John S. Fox, MBA, PhD, MIoD TD
John is a biochemist by training and has over 30 years’ experience of pharmaceutical development gained in both multinational and early stage biotech companies. He is currently Chief Executive Officer of Transcriptogen Ltd, an early stage company developing novel oncology compounds based on transcription factor inhibition. His career has covered a number of therapeutic areas, and has involved directing all relevant development functions from bench to late phase regulatory studies. After serving as Director of Planning for Shire Pharmaceuticals, John co-founded and was Chief Operating Officer of Hunter Fleming, a start-up company with an early stage portfolio derived from University research and focused on neuroprotection. After Hunter Fleming was acquired by Newron SpA, John joined Merrion Pharmaceuticals Ltd, a drug delivery company based in Dublin, as Chief Development Officer and subsequently Chief Executive.

Having recently relocated back to the United Kingdom, John has kept an interest in supporting university spin-outs and translational research and has been involved in advising new companies in both UK and Ireland. He has been engaged for many years in non-executive roles in university technology transfer and SME Boards.

Dr. Le Roy Dowey
Dr. Le Roy DoweyBoard Member - CEO
Dr Le Roy Dowey has joined GreenLight from Ulster University, where he worked with academics, clinicians, local councils, funding agencies, and companies ranging from entrepreneurs and SMEs to multinationals, to deliver Innovation Vouchers and Commercial Contract Research, including nutritional and clinical trials.

Le Roy obtained a BSc (Hons) in Biochemistry from Queen’s University, Belfast and a PhD in Nutritional Biochemistry at Ulster University (2002). After a period of post-doctoral research, he became Quality Assurance Officer for Ulster’s Biomedical Sciences Research Institute (BMSRI). Le Roy set up the BMSRI Core Facility Units to support academic and commercial research, and since 2012 he has worked with colleagues to bring over £17.5m of research and innovation funding into the University and NI. In 2015 he was appointed Commercial Manager at C-TRIC (Clinical Translational Research Innovation Centre) where he worked closely with the Western Health and Social Care Trust, Ulster University, Derry City & Strabane District Council, North West Regional College, lnvestNI and local companies, to develop economic growth and supply bio-businesses with support and advice. Le Roy returned to Ulster as BMSRI’s Business Development Manager, managing the Core Facility Units and an expert team of Scientific Assistants/Officers.

Le Roy joined the GreenLight Team in June 2018 as Director of Corporate Development and is now Chief Executive Officer.

Patrick Deasy
Patrick Deasy Board Member - CFO
Patrick Deasy has spent 20 years as CEO and CFO of international clinical research organisations (CROs) during which time he was responsible for the development and integration of international operations in Germany, the Netherlands, the UK, Spain, Hungary and South Africa
Dr. James Linden
Dr. James LindenFounder / Non-Executive Director
James achieved his PhD in Biochemistry in the Department of Ophthalmology, Queens University Belfast. After a year of researching Alzheimer’s Diseases as a Post-Doc in Neuroscience, Trinity College Dublin, James left the academic world and moved into pharmaceutical sales. After gaining sales experience he then went on to form his own generic drug company in Ireland called Éireceutica Ltd. Here he learned many skills and attributes which he has carried forth into his latest brain-child, GreenLight Medicines. As a scientist and a pharma expert James had the perfect skill set to build GreenLight’s world-beating research network and also to identify which products should be developed and which markets they should be developed for.
Lars Müller
Lars MüllerNon-Executive Director
Lars is an entrepreneur with over ten years of valuable experience growing successful companies. He has vast knowledge in the areas of genetics, extraction methods and product development and has been involved in the cannabinoid industry since 2015.
Thomas Hanke
Thomas HankeNon-Executive Director
Thomas is experienced in venture capital, private equity and growth capital.
He has extensive knowledge of the investment industry and portfolio management.
Greg Eastwood
Greg EastwoodNon-Executive Director
Greg is a qualified mechanical engineer with a strong background in research and development. Greg spent 35 years working in California, a focus of which included securing hold patents internationally in the U.S.A, Canada and China. Previously Greg has served as company President of a large engineering firm.